Evidence map›Paper›PMID 26976708›Full record

ArticleArchives of biochemistry and biophysics2016

Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice.

Cristobal L Miranda, Valerie D Elias, Joshua J Hay, Jaewoo Choi, Ralph L Reed, Jan F Stevens

Open access · greenAbstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 99 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cristobal L MirandaLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Valerie D EliasLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Joshua J HayLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Jaewoo ChoiLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Ralph L ReedLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.
Jan F StevensLinus Pauling Institute and Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA. Electronic address: fred.stevens@oregonstate.edu.
Oregon State University · US

Funding

Vitamin D, Xanthohumol and Nuclear Receptors: Targeting Immunity, Microbiota andR01AT009168 · NCCIH · OREGON STATE UNIVERSITY · PI GOMBART, ADRIAN FRIEDRICH, MAIER, CLAUDIA S · 2015 to 2019
$3.0M
Triple Quadrupole/Linear Ion Trap LC-MS/MS for LPIS10RR027878 · NCRR · OREGON STATE UNIVERSITY · PI STEVENS, JAN FREDERIK · 2010 to 2010
$484k
HYBRID TRIPLE QUADRUPOLE LINEAR ION TRAP MASS SPECTROMETER: PROSTATE CANCERS10RR022589 · NCRR · OREGON STATE UNIVERSITY · PI STEVENS, JAN FREDERIK · 2006 to 2006
$343k
NCCIH NIH HHS R01 AT009168NCRR NIH HHS S10 RR022589NCRR NIH HHS S10 RR027878
6 · The paper itself

Abstract

Xanthohumol (XN) is a prenylated flavonoid found in hops (Humulus lupulus) and beer. The dose-dependent effects of XN on glucose and lipid metabolism in a preclinical model of metabolic syndrome were the focus of our study. Forty-eight male C57BL/6J mice, 9 weeks of age, were randomly divided into three XN dose groups of 16 animals. The mice were fed a high-fat diet (60% kcal as fat) supplemented with XN at dose levels of 0, 30, or 60 mg/kg body weight/day, for 12 weeks. Dietary XN caused a dose-dependent decrease in body weight gain. Plasma levels of glucose, total triglycerides, total cholesterol, and MCP-1 were significantly decreased in mice on the 60 mg/kg/day treatment regimen. Treatment with XN at 60 mg/kg/day resulted in reduced plasma LDL-cholesterol (LDL-C), IL-6, insulin and leptin levels by 80%, 78%, 42%, and 41%, respectively, compared to the vehicle control group. Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) levels were 44% lower in the 60 mg/kg dose group compared to the vehicle control group (p ≤ 0.05) which may account for the LDL-C lowering activity of XN. Our results show that oral administration of XN improves markers of systemic inflammation and metabolic syndrome in diet-induced obese C57BL/6J mice.

Indexed as

AnimalsBlood GlucoseCarbohydrate MetabolismCholesterol, LDLDietary FatsFlavonoidsHumulusInsulinInterleukin-6LeptinLipid MetabolismLiverMaleMiceObesityPropiophenonesBlood GlucoseCholesterol, LDLDietary FatsFlavonoidsInsulinInterleukin-6interleukin-6, mouseLeptinPcsk9 protein, mousePropiophenonesProprotein Convertase 9xanthohumolC57BL/6J miceLipidomicsMetabolic syndromeObesityPCSK9Xanthohumol

Identifiers

PMID26976708
PMCPMC4875845
OpenAlexW2298344241

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.